

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3DMed

思路迪

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

**CLARIFICATION ANNOUNCEMENT
REGARDING THE ANNUAL RESULTS ANNOUNCEMENT FOR
THE YEAR ENDED DECEMBER 31, 2023**

Reference is made to the announcement dated March 28, 2024 (the “**Announcement**”) issued by 3D Medicines Inc. (the “**Company**”) in respect of the annual results for the year ended December 31, 2023. Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Company would like to clarify that the paragraph headed “Management Discussion and Analysis – Other Business Development – 2. Cooperative Development of mRNA Therapeutic Tumor Vaccines” shall be deleted in its entirety and be replaced as follows:

“The Company brings valuable global experience in the development and commercialization of innovative drugs, evidenced by the cumulative sales of its first commercialized product, 恩維達®, exceeding RMB1 billion. The CanSino Biologics Inc. team possesses extensive expertise in mRNA vaccine research and process scale-up.”

Further, the Company wishes to replace the paragraphs headed (i) “Financial Highlights – IFRSs Measures – 5. Selling and Marketing Expenses” and (ii) “Management Discussion and Analysis – Financial Overview – Selling and Marketing Expenses” with the following in its entirety:

“During the Reporting Period, our selling and marketing expenses mainly represented expenses for promoting 恩維達® in China in accordance with industry standards to boost sales. Our selling and marketing expenses increased by 5.9% from RMB357.7 million for the year ended December 31, 2022 to RMB378.8 million for the year ended December 31, 2023. The increase was attributed to the sales growth of 恩維達 when the sales revenue growth rate for 2023 (i.e. 11.9%) exceeded the growth rate of selling and marketing expenses in the same period (i.e. 5.9%).”

This clarification announcement is supplemental to and should be read in conjunction with the Announcement. Save as disclosed above, the Board confirms that the above clarifications do not affect the other information and contents contained in the Announcement which remain correct and unchanged.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong
April 3, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.